Evidence map›Paper›PMID 35255971›Full record

ArticleBMC research notes2022

Plasma Neuron-Specific Enolase is not a reliable biomarker for staging Trypanosoma brucei rhodesiense sleeping sickness patients.

Charles D Kato, Dorothy Twesigye, Vincent P Alibu, Ann Nanteza, Julius Nsubuga, Claire M Mugasa, Enock Matovu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Charles D KatoSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda. katodrago@gmail.com.ORCID http://orcid.org/0000-0003-3160-6657
Dorothy TwesigyeSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda.
Vincent P AlibuCollege of Natural Sciences, Makerere University, P.O Box 7062, Kampala, Uganda.
Ann NantezaSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda.
Julius NsubugaSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda.
Claire M MugasaSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda.
Enock MatovuSchool of Bio-Security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-Security, Makerere University, P.O Box 7062, Kampala, Uganda.
Makerere University · UG

Funding

European and Developing Countries Clinical Trials Partnership TMA2017CDF- 1887
6 · The paper itself

Abstract

objectiveCurrently, the only available staging criterion for T. b. rhodesiense requires a lumber puncture to collect and later examine cerebrospinal fluid (CSF). This study examined the potential of plasma Neuron-Specific Enolase (NSE) in discriminating between early and late-stage patients.

resultsWhen median NSE levels were compared between early and late-stage patients, results showed a significant (P < 0.02) upregulation among late-stage patients (599.8 ng/mL). No significant differences (P > 0.9) in NSE levels were observed between early-stage patients (300 ng/mL) and controls (454 ng/mL). We used Receiver Operator Characteristic (ROC) curves to explore the likelihood of using plasma NSE as a potential stage biomarker in discriminating between early and late-stage HAT patients. Our results showed that NSE demonstrated an area under the curve (AUC) of 0.702 (95% CI 0.583-0.830). A high staging accuracy for NSE was obtained by using a cutoff of > 346.5 ng/mL with a sensitivity of 68.6% (95% CI 55-79.7%) and a specificity of 93.3% (95% CI 70.2-99.7%). Although our results demonstrate that plasma NSE is upregulated in T. b. rhodesiense sleeping sickness patients, its value in discriminating between late and early-stage patients is limited. However, future studies could consider improving its specificity by combining it with other identified plasma biomarkers.

Indexed as

Trypanosoma brucei rhodesienseTrypanosomiasis, AfricanAnimalsBiomarkersHumansPhosphopyruvate HydratasePlasmaBiomarkersPhosphopyruvate HydrataseBiomarkerHuman African trypanosomiasisNeuron-Specific EnolaseSleeping sickness

Identifiers

PMID35255971
PMCPMC8900431
OpenAlexW4220841752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.